Clinical Trial Update: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Brentuximab Vedotin plus Rituximab with dose-attenuated CHP in elderly patients with diffuse large B-cell lymphoma; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Patrick Reagan | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING